EUVIMEDEUVIMED entdecken
Crossref

Precision medicine for psychotic disorders: objective assessment, risk prediction, and pharmacogenomics

M D Hill, S S Gill iD, H Le-Niculescu, O MacKie, R Bhagar, K Roseberry, O K Murray iD, H D Dainton, S K Wolf, A Shekhar, S M Kurian, A B Niculescu iD

Molecular Psychiatry · 2024

DOI: 10.1038/s41380-024-02433-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Psychiatry, 2024. Verfasst von M D Hill und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA. Hauptthemen laut MEDLINE: Precision Medicine, Psychotic Disorders, Pharmacogenetics, Biomarkers. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: CSRD VA, U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH), U.S. Department of Veterans Affairs (Department of Veterans Affairs).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psychosis occurs inside the brain, but may have external manifestations (peripheral molecular biomarkers, behaviors) that can be objectively and quantitatively measured. Blood biomarkers that track core psychotic manifestations such as hallucinations and delusions could provide a window into the biology of psychosis, as well as help with diagnosis and treatment. We endeavored to identify objective blood gene expression biomarkers for hallucinations and delusions, using a stepwise discovery, prioritization, validation, and testing in independent cohorts design. We were successful in identifying biomarkers that were predictive of high hallucinations and of high delusions states, and of future psychiatric hospitalizations related to them, more so when personalized by gender and diagnosis. Top biomarkers for hallucinations that survived discovery, prioritization, validation and testing include PPP3CB, DLG1, ENPP2, ZEB2, and RTN4. Top biomarkers for delusions include AUTS2, MACROD2, NR4A2, PDE4D, PDP1, and RORA. The top biological pathways uncovered by our work are glutamatergic synapse for hallucinations, as well as Rap1 signaling for delusions. Some of the biomarkers are targets of existing drugs, of potential utility in pharmacogenomics approaches (matching patients to medications, monitoring response to treatment). The top biomarkers gene expression signatures through bioinformatic analyses suggested a prioritization of existing medications such as clozapine and risperidone, as well as of lithium, fluoxetine, valproate, and the nutraceuticals omega-3 fatty acids and magnesium. Finally, we provide an example of how a personalized laboratory report for doctors would look. Overall, our work provides advances for the improved diagnosis and treatment for schizophrenia and other psychotic disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicinePsychotic DisordersPharmacogeneticsBiomarkersHumansMaleFemaleHallucinationsAntipsychotic AgentsDelusionsAdultRisk AssessmentSchizophrenia

Substanzen

BiomarkersAntipsychotic Agents

Autor:innen und Institutionen

  • Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA.
  • Indianapolis VA Medical Center, Indianapolis, IN, USA.
  • Stark Neuroscience Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.
  • Department of Neurology, Medical University of South Carolina, Charleston, SC, USA.
  • Department of Neurology, Ohio State University Medical Center, Columbus, OH, USA.
  • Office of the Dean, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

ORCID-Profile: S S Gill, O K Murray, A B Niculescu

Förderung

  • CSRD VA
  • U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
  • U.S. Department of Veterans Affairs (Department of Veterans Affairs)
  • NIMH NIH HHS

Zitieren

APA

Hill, M. D., Gill, S. S., Le-Niculescu, H., MacKie, O., Bhagar, R., Roseberry, K., Murray, O. K., Dainton, H. D., Wolf, S. K., Shekhar, A., Kurian, S. M., & Niculescu, A. B. (2024). Precision medicine for psychotic disorders: objective assessment, risk prediction, and pharmacogenomics. Molecular Psychiatry. https://doi.org/10.1038/s41380-024-02433-8

Vancouver

Hill MD, Gill SS, Le-Niculescu H, MacKie O, Bhagar R, Roseberry K, et al. Precision medicine for psychotic disorders: objective assessment, risk prediction, and pharmacogenomics. Molecular Psychiatry. 2024. doi:10.1038/s41380-024-02433-8

BibTeX
@article{Hill2024,
  author = {Hill, M D and Gill, S S and Le-Niculescu, H and MacKie, O and Bhagar, R and Roseberry, K and Murray, O K and Dainton, H D and Wolf, S K and Shekhar, A and Kurian, S M and Niculescu, A B},
  title = {Precision medicine for psychotic disorders: objective assessment, risk prediction, and pharmacogenomics},
  journal = {Molecular Psychiatry},
  year = {2024},
  doi = {10.1038/s41380-024-02433-8}
}
Kostenlos starten →